Clinical Trial

Adaptive Radiation for Abdominopelvic Metastases

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no greater than 10%. Subjects with metastatic cancer to the abdomen or pelvis requiring local control or palliation will be enrolled.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-05-19; most recent amendment 2025-10-28.
Status change: Not Yet Recruiting → Recruiting 2023-09-05
Trial Details
NCT Number NCT05880667
Lead Sponsor Fox Chase Cancer Center
Conditions Neoplasm - Soft Tissue Pelvis Malignant Secondary, Malignant Neoplasm of Stomach
Enrollment 30 participants
Start Date 2023-08-01
Primary Completion 2028-06-01 (estimated)
Study Completion 2029-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-29